<SEC-DOCUMENT>0001140361-23-058974.txt : 20231222
<SEC-HEADER>0001140361-23-058974.hdr.sgml : 20231222
<ACCEPTANCE-DATETIME>20231221202719
ACCESSION NUMBER:		0001140361-23-058974
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		14
CONFORMED PERIOD OF REPORT:	20231221
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20231222
DATE AS OF CHANGE:		20231221

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			IONIS PHARMACEUTICALS INC
		CENTRAL INDEX KEY:			0000874015
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				330336973
		STATE OF INCORPORATION:			CA
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-19125
		FILM NUMBER:		231506929

	BUSINESS ADDRESS:	
		STREET 1:		2855 GAZELLE COURT
		CITY:			CARLSBAD
		STATE:			CA
		ZIP:			92010
		BUSINESS PHONE:		7609319200

	MAIL ADDRESS:	
		STREET 1:		2855 GAZELLE COURT
		CITY:			CARLSBAD
		STATE:			CA
		ZIP:			92010

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ISIS PHARMACEUTICALS INC
		DATE OF NAME CHANGE:	19930328
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>ef20017247_form8k.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<html xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:srt="http://fasb.org/srt/2023" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:country="http://xbrl.sec.gov/country/2023" xmlns:currency="http://xbrl.sec.gov/currency/2023" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:naics="http://xbrl.sec.gov/naics/2023" xmlns:sic="http://xbrl.sec.gov/sic/2023" xmlns:stpr="http://xbrl.sec.gov/stpr/2023" xmlns:exch="http://xbrl.sec.gov/exch/2023" xmlns:cef="http://xbrl.sec.gov/cef/2023" xmlns:ions="http://ionispharma.com/20231221" xmlns="http://www.w3.org/1999/xhtml">
  <head>
    <title></title>
    <!-- Licensed to: Broadridge
         Document created using Broadridge PROfile 23.12.1.5186
         Copyright 1995 - 2023 Broadridge -->
    <meta http-equiv="Content-Type" content="text/html" />
</head>

<body style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; background-color: #ffffff;">
<div id="DSPFiXBRLHidden" style="display: none;"><ix:header><ix:hidden><ix:nonNumeric name="dei:AmendmentFlag" id="Fact_08f36272673a41639eb79c935ec285bd" contextRef="c20231221to20231221" format="ixt:fixed-false">false</ix:nonNumeric><ix:nonNumeric name="dei:EntityCentralIndexKey" id="Fact_1ca1adae07104a16ab67f2e2f244dc4d" contextRef="c20231221to20231221">0000874015</ix:nonNumeric><ix:nonNumeric name="dei:EntityAddressStateOrProvince" id="Fact_0ffbb164a53e46cd96f7d165925db3ab" contextRef="c20231221to20231221">CA</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:href="ions-20231221.xsd" xlink:type="simple"></link:schemaRef></ix:references><ix:resources><xbrli:context id="c20231221to20231221"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-12-21</xbrli:startDate><xbrli:endDate>2023-12-21</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div>

  <div>
    <hr style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;" />
    <div> <br />
    </div>

    <div>
      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 14pt; font-weight: bold;">SECURITIES AND EXCHANGE COMMISSION</div>

      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 12pt; font-weight: bold;">Washington, D.C. 20549</div>

      <div><br />
      </div>

      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 18pt; font-weight: bold;">FORM <ix:nonNumeric name="dei:DocumentType" id="Fact_89b20f448000484a99378cc870c89f20" contextRef="c20231221to20231221">8-K</ix:nonNumeric></div>

      <div><br />
      </div>

      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">CURRENT REPORT</div>

      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">PURSUANT TO SECTION 13 OR 15(d) OF THE</div>

      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">SECURITIES EXCHANGE ACT OF 1934</div>

      <div><br />
      </div>

      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;">Date of report (Date of earliest event reported): <ix:nonNumeric name="dei:DocumentPeriodEndDate" id="Fact_95f843f3b2e044e5829f63a6fee94472" contextRef="c20231221to20231221" format="ixt:date-monthname-day-year-en">December 21, 2023</ix:nonNumeric></div>

      <div><br />
      </div>

      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 24pt; font-weight: bold;"><ix:nonNumeric name="dei:EntityRegistrantName" id="Fact_f0eac010c4ef4cc79b535e678e24bdb6" contextRef="c20231221to20231221">IONIS PHARMACEUTICALS, INC.</ix:nonNumeric><br />
      </div>

      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;">(Exact Name of Registrant as Specified in Charter)</div>

      <div><br />
      </div>

      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" id="Fact_a946e6491aa24db190b18e8d84b2e900" contextRef="c20231221to20231221" format="ixt-sec:stateprovnameen">Delaware</ix:nonNumeric><br />
      </div>

      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;">(State or Other Jurisdiction of Incorporation)</div>

      <div><br />
      </div>

      <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">


  <tr>

    <td style="width: 50%; vertical-align: top;">
              <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"><ix:nonNumeric name="dei:EntityFileNumber" id="Fact_94cfa8cd7b324aaebeb3c76e92900d06" contextRef="c20231221to20231221">000-19125</ix:nonNumeric><br />
              </div>
            </td>

    <td style="width: 50%; vertical-align: top;">
              <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"><ix:nonNumeric name="dei:EntityTaxIdentificationNumber" id="Fact_dd23466dc8e9489f826cad885ea0271a" contextRef="c20231221to20231221">33-0336973</ix:nonNumeric><br />
              </div>
            </td>

  </tr>

  <tr>

    <td style="width: 50%; vertical-align: top;">
              <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;">(Commission File No.)</div>
            </td>

    <td style="width: 50%; vertical-align: top;">
              <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;">(IRS Employer Identification No.)</div>
            </td>

  </tr>


</table>
      <div><br />
      </div>

      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"><ix:nonNumeric name="dei:EntityAddressAddressLine1" id="Fact_e9ac437091c44ab58b8a5dbe2685e435" contextRef="c20231221to20231221">2855 Gazelle Court</ix:nonNumeric><br />
      </div>

      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"><ix:nonNumeric name="dei:EntityAddressCityOrTown" id="Fact_8192bcc8d18441358b3171e8d46de8e4" contextRef="c20231221to20231221">Carlsbad</ix:nonNumeric>, <span style="-sec-ix-hidden:Fact_0ffbb164a53e46cd96f7d165925db3ab">CA</span> <ix:nonNumeric name="dei:EntityAddressPostalZipCode" id="Fact_33aa7c5ae18b44ecb7a801eb3ce20cb4" contextRef="c20231221to20231221">92010</ix:nonNumeric></div>

      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;">(Address of Principal Executive Offices and Zip Code)</div>

      <div><br />
      </div>

      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;">Registrant&#8217;s telephone number, including area code: <span style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">(<ix:nonNumeric name="dei:CityAreaCode" id="Fact_93d2a473fc3643edbef4cb32ddff945c" contextRef="c20231221to20231221">760</ix:nonNumeric>) <ix:nonNumeric name="dei:LocalPhoneNumber" id="Fact_aa9b67e90712488a884e99d54f2e0c6e" contextRef="c20231221to20231221">931-9200</ix:nonNumeric></span></div>

      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;"> <br />
        </span></div>

      <div>
        <hr style="height: 2px; color: #000000; background-color: #000000; text-align: center; border: none; margin-left: auto; margin-right: auto;" /></div>

      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following
        provisions:</div>

      <div><br />
      </div>

      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 18pt; vertical-align: top; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonNumeric name="dei:WrittenCommunications" id="Fact_45bcea51a37d4c56ab869e6f16ac6ca2" contextRef="c20231221to20231221" format="ixt-sec:boolballotbox">&#x2610;</ix:nonNumeric><br />
            </td>

    <td style="width: auto; vertical-align: top; text-align: left;">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</div>
            </td>

  </tr>


</table>
      <div><br />
      </div>

      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 18pt; vertical-align: top; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonNumeric name="dei:SolicitingMaterial" id="Fact_2cf270e88d4b4a4cac0b2556b9da4630" contextRef="c20231221to20231221" format="ixt-sec:boolballotbox">&#x2610;</ix:nonNumeric><br />
            </td>

    <td style="width: auto; vertical-align: top; text-align: left;">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</div>
            </td>

  </tr>


</table>
      <div><br />
      </div>

      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 18pt; vertical-align: top; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonNumeric name="dei:PreCommencementTenderOffer" id="Fact_b7cc4a902dde4bb7823889967a191323" contextRef="c20231221to20231221" format="ixt-sec:boolballotbox">&#x2610;</ix:nonNumeric><br />
            </td>

    <td style="width: auto; vertical-align: top; text-align: left;">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</div>
            </td>

  </tr>


</table>
      <div><br />
      </div>

      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 18pt; vertical-align: top; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonNumeric name="dei:PreCommencementIssuerTenderOffer" id="Fact_3d11b2f6aa8848ea864d70236c9ea162" contextRef="c20231221to20231221" format="ixt-sec:boolballotbox">&#x2610;</ix:nonNumeric><br />
            </td>

    <td style="width: auto; vertical-align: top; text-align: left;">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</div>
            </td>

  </tr>


</table>
      <div><br />
      </div>

      <div style="text-align: left; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">Securities registered pursuant to Section 12(b) of the Act:</div>

      <div><br />
      </div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">


  <tr>

    <td style="width: 31.1%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="text-align: center; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">Title of each class</div>
            </td>

    <td style="width: 4.7%; vertical-align: top; padding-bottom: 2px;">&#160;</td>

    <td style="width: 17.22%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="text-align: center; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">Trading symbol</div>
            </td>

    <td style="width: 4.57%; vertical-align: top; padding-bottom: 2px;">&#160;</td>

    <td style="width: 42.41%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="text-align: center; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">Name of each exchange on which registered</div>
            </td>

  </tr>

  <tr>

    <td style="width: 31.1%; vertical-align: top;">
              <div style="text-align: center; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonNumeric name="dei:Security12bTitle" id="Fact_98579f8db1df496c9332dd09158e555d" contextRef="c20231221to20231221">Common Stock, $.001 Par Value</ix:nonNumeric><br />
              </div>
            </td>

    <td style="width: 4.7%; vertical-align: top;">&#160;</td>

    <td style="width: 17.22%; vertical-align: top;">
              <div style="text-align: center; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">&#8220;<ix:nonNumeric name="dei:TradingSymbol" id="Fact_d3aaf440913c4fb19c44fe6b95d3296d" contextRef="c20231221to20231221">IONS</ix:nonNumeric>&#8221;</div>
            </td>

    <td style="width: 4.57%; vertical-align: top;">&#160;</td>

    <td style="width: 42.41%; vertical-align: top;">
              <div style="text-align: center; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonNumeric name="dei:SecurityExchangeName" id="Fact_8b6374e783fb4760bf287cd657c8e896" contextRef="c20231221to20231221" format="ixt-sec:exchnameen">The Nasdaq Stock Market, LLC</ix:nonNumeric><br />
              </div>
            </td>

  </tr>


</table>
      <div><br />
      </div>

      <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (Section 230.405 of this chapter) or
        Rule 12b-2 of the Securities Exchange Act of 1934 (Section 240.12b-2 of this chapter).</div>

      <div><br />
      </div>

      <div style="text-align: right; font-family: 'Times New Roman'; font-size: 10pt;">Emerging growth company&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<a id="z_Hlk11148519"></a><ix:nonNumeric name="dei:EntityEmergingGrowthCompany" id="Fact_050419c23fbe4f628d24e8e02c9547b8" contextRef="c20231221to20231221" format="ixt-sec:boolballotbox">&#x2610;</ix:nonNumeric></div>

      <div><br />
      </div>

      <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised
        financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.</div>

      <div style="text-align: right; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">&#9744;</div>

      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">
        <hr style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;" /> </div>

      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageFooter"></div>

        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

        <div class="BRPFPageHeader"></div>

      </div>

      <div><br />
      </div>

      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 54pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Item 8.01</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Other Events.</div>
            </td>

  </tr>


</table>
      <div><br />
      </div>

      <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">On December 21, 2023, Ionis Pharmaceuticals, Inc. (&#8220;<span style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; font-style: italic;">Ionis</span>&#8221;)
        issued a press release announcing that the U.S. Food and Drug Administration has approved Ionis&#8217; and AstraZeneca&#8217;s WAINUA&#8482; (eplontersen) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults.</div>

      <div><br />
      </div>

      <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">A copy of this press release is attached as Exhibit 99.1 to this Current Report and incorporated herein by reference.</div>

      <div><br />
      </div>

      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 54pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Item 9.01.</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Financial Statements and Exhibits.</div>
            </td>

  </tr>


</table>
      <div><br />
      </div>

      <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">(d) Exhibits.</div>

      <div><br />
      </div>

      <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">


  <tr>

    <td style="width: 15%; vertical-align: top;">
              <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"><span style="text-decoration: underline;">Exhibit No.</span></div>
            </td>

    <td style="width: 85%; vertical-align: top;">
              <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"><span style="text-decoration: underline;">Description</span></div>
            </td>

  </tr>

  <tr>

    <td style="width: 15%; vertical-align: top;">
              <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;"><a href="ef20017247_ex99-1.htm">99.1</a></div>
              <div>&#160;</div>
              <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;">104</div>
            </td>

    <td style="width: 85%; vertical-align: top;">
              <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Press Release dated December 21, 2023.</div>
              <div>&#160;</div>
              <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Cover Page Interactive Data File (embedded within the Inline XBRL document).</div>
            </td>

  </tr>


</table>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-variant: small-caps; font-weight: bold;">&#160;</div>

      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageFooter"></div>

        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

        <div class="BRPFPageHeader"></div>

      </div>

      <div><br />
      </div>

      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-variant: small-caps; font-weight: bold;">SIGNATURE</div>

      <div><br />
      </div>

      <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its
        behalf by the undersigned, thereunto duly authorized.</div>

      <div><br />
      </div>

      <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">


  <tr>

    <td style="width: 50%; vertical-align: top;">&#160;</td>

    <td style="width: 5%; vertical-align: top;" rowspan="1" colspan="2">
              <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; font-variant: small-caps; font-weight: bold;">Ionis Pharmaceuticals, Inc.</div>
            </td>

    <td style="width: 10%; vertical-align: top;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 50%; vertical-align: top;">&#160;</td>

    <td style="width: 5%; vertical-align: top;">&#160;</td>

    <td style="width: 35%; vertical-align: top;">&#160;</td>

    <td style="width: 10%; vertical-align: top;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 50%; vertical-align: top;">
              <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">Dated: December 21, 2023</div>
            </td>

    <td style="width: 5%; vertical-align: top;">
              <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">By:</div>
            </td>

    <td style="width: 35%; vertical-align: top; border-bottom: 2px solid black;">
              <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">/s/ Patrick R. O&#8217;Neil</div>
            </td>

    <td style="width: 10%; vertical-align: top;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 50%; vertical-align: top;">&#160;</td>

    <td style="width: 5%; vertical-align: top;">&#160;</td>

    <td style="width: 35%; vertical-align: top;">
              <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; font-variant: small-caps; font-weight: bold;">Patrick R. O&#8217;Neil</div>
            </td>

    <td style="width: 10%; vertical-align: top;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 50%; vertical-align: top;">&#160;</td>

    <td style="width: 5%; vertical-align: top;">&#160;</td>

    <td style="width: 35%; vertical-align: top;">
              <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">Executive Vice President, Chief Legal Officer and General Counsel</div>
            </td>

    <td style="width: 10%; vertical-align: top;">&#160;</td>

  </tr>


</table>
      <div><br />
      </div>

      <div><br />
      </div>

      <div>
        <hr style="height: 2px; color: #000000; background-color: #000000; text-align: center; border: none; margin-left: auto; margin-right: auto;" /></div>

    </div>

  </div>

</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ef20017247_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Broadridge
         Document created using Broadridge PROfile 23.12.1.5186
         Copyright 1995 - 2023 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <hr noshade="noshade" align="center" style="height: 4px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;">
    <div style="text-align: right;"><font style="font-weight: bold;">Exhibit 99.1</font><br>
    </div>
    <div> <br>
    </div>
    <div> <img src="logo1.jpg">
      <div><br>
      </div>
      <div>
        <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">WAINUA&#8482; (eplontersen) granted regulatory approval in the U.S. for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated
          amyloidosis</div>
        <div><br>
        </div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z9020b413904842899ecf400d35059acd">

            <tr>
              <td style="width: 54pt;"><br>
              </td>
              <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#8226;</td>
              <td style="width: auto; vertical-align: top; text-align: left;">
                <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: italic;">U.S. FDA approval based on Phase 3 NEURO-TTRansform results showing WAINUA demonstrated consistent and sustained benefit halting neuropathy disease
                  progression and improving neuropathy impairment and quality of life</div>
              </td>
            </tr>

        </table>
        <div><br>
        </div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z53dd734d1f964c63ab14308d2a0515c5">

            <tr>
              <td style="width: 54pt;"><br>
              </td>
              <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#8226;</td>
              <td style="width: auto; vertical-align: top; text-align: left;">
                <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: italic;">Additional regulatory reviews for WAINUA underway in rest of world</div>
              </td>
            </tr>

        </table>
        <div><br>
        </div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zd0cfb44d6ade49ebb5700f0a66e37c2e">

            <tr>
              <td style="width: 54pt;"><br>
              </td>
              <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#8226;</td>
              <td style="width: auto; vertical-align: top; text-align: left;">
                <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: italic;">WAINUA will be available in the U.S. in January 2024</div>
              </td>
            </tr>

        </table>
        <div><br>
        </div>
        <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">CARLSBAD, Calif., Dec. 21, 2023</font> &#8211; <font style="font-size: 10pt; font-family: 'Times New Roman';">Ionis Pharmaceuticals, Inc.</font> (Nasdaq: IONS) announced today that the U.S. Food and Drug Administration (FDA) has approved Ionis and AstraZeneca&#8217;s WAINUA&#8482; (eplontersen) for the treatment of the polyneuropathy of
          hereditary transthyretin-mediated amyloidosis in adults, commonly referred to as hATTR-PN or ATTRv-PN. WAINUA is the only approved medicine for the treatment of ATTRv-PN that can be self-administered via an auto-injector.</div>
        <div><br>
        </div>
        <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">The approval was based on the <font style="font-size: 10pt; font-family: 'Times New Roman';">positive 35-week interim analysis from the Phase 3 NEURO-TTRansform study</font>
          which showed patients treated with WAINUA demonstrated consistent and sustained benefit on the co-primary endpoints of serum transthyretin (TTR) concentration and neuropathy impairment measured by modified Neuropathy Impairment Score +7 (mNIS+7),
          and key secondary endpoint of quality of life (QoL) on the Norfolk Quality of Life Questionnaire-Diabetic Neuropathy (Norfolk QoL-DN). Positive results from the Phase 3 NEURO-TTRansform study were published in <font style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic;">The Journal of the American Medical Association </font><font style="font-size: 10pt; font-family: 'Times New Roman';">(JAMA)</font><font style="font-size: 10pt; font-family: 'Times New Roman'; color: #3C4242;">&#160;</font>further demonstrating the benefit of WAINUA across the spectrum of ATTRv-PN at 35, 66 and 85-weeks.</div>
        <div><br>
        </div>
        <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">&#8220;Many people living with hereditary transthyretin-mediated amyloid polyneuropathy are unable to fully enjoy their lives because of the relentless, progressive and
          debilitating effects of the disease,&#8221; said Michael J. Polydefkis, M.D., professor of neurology at Johns Hopkins University School of Medicine and an investigator in the NEURO-TTRansform study. &#8220;Approval of WAINUA represents a meaningful
          advancement in treatment, one that gives those who are living with transthyretin-mediated amyloid polyneuropathy help managing the disease.&#8221;</div>
        <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
          <div style="page-break-after: always;" class="BRPFPageBreak">
            <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
        </div>
        <div><br>
        </div>
        <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">ATTRv-PN is a debilitating disease that leads to peripheral nerve damage with motor disability within five years of diagnosis and, without treatment, is generally fatal
          within a decade. WAINUA is a ligand-conjugated antisense <font style="font-size: 10pt; font-family: 'Times New Roman';">oligonucleotide </font>(LICA) medicine designed to reduce the production of TTR protein at its source.</div>
        <div><br>
        </div>
        <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">&#8220;The FDA approval of WAINUA marks an important milestone for people living with hereditary transthyretin-mediated amyloid polyneuropathy, who will now have an
          effective, well-tolerated treatment that can be self-administered via auto-injector to combat this devastating disease,&#8221; said Brett P. Monia, Ph.D., chief executive officer at Ionis. &#8220;It is also a pivotal moment for Ionis as WAINUA will be the
          first in a steady cadence of potential commercial launches for the company. We are proud to have discovered and, together with AstraZeneca, developed WAINUA, and are grateful to the patients, caregivers and investigators who participated in our
          clinical studies, as well as for the dedication of our scientists and researchers.&#8221;</div>
        <div><br>
        </div>
        <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">&#8220;People with hereditary transthyretin-mediated amyloid polyneuropathy, and other forms of amyloidosis, are often misdiagnosed since symptoms can mirror other
          conditions,&#8221; said Isabelle Lousada, President and CEO, Amyloidosis Research Consortium &#8220;The path to getting an accurate diagnosis can often be a long, arduous journey and it is critical that a timely and accurate diagnosis is made not only for
          the individual experiencing symptoms but for their families and loved ones. It is exciting to see new innovations coming through and increased efforts to raise awareness in an area that has often been overlooked or neglected.&#8221;</div>
        <div><br>
        </div>
        <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">WAINUA will be available in the U.S. in January 2024.</div>
        <div><br>
        </div>
        <div style="text-align: left; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">&#8220;There is an urgent medical need for new therapies for people living with hereditary transthyretin-mediated amyloid polyneuropathy, as well as earlier,
          accurate diagnosis of this systemic, progressive and fatal condition.&#8221; said Ruud Dobber, executive vice president, BioPharmaceuticals Business Unit, AstraZeneca. &#8220;The U.S. approval of WAINUA offers a new treatment option that provides consistent
          and sustained reduction in serum TTR concentration compared to baseline while halting disease progression and improving quality of life for people living with this debilitating condition.&#8221;</div>
        <div><br>
        </div>
        <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">As part of a <font style="font-size: 10pt; font-family: 'Times New Roman';">global development and commercialization agreement</font>, AstraZeneca and Ionis will
          commercialize WAINUA for the treatment of ATTRv-PN in the U.S. and are seeking regulatory approval in Europe and other parts of the world. This agreement was recently expanded to include exclusive rights for AstraZeneca to commercialize WAINUA in
          Latin America in addition to all other countries outside the U.S.<sup style="color: #000000; vertical-align: text-top; line-height: 1; font-size: smaller;">&#160;</sup>WAINUA was granted Orphan Drug Designation in the U.S. and in the EU for the treatment of transthyretin-mediated amyloidosis (ATTR).</div>
        <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
          <div style="page-break-after: always;" class="BRPFPageBreak">
            <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
        </div>
        <div><br>
        </div>
        <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Eplontersen is <font style="font-size: 10pt; font-family: 'Times New Roman';">currently being evaluated in the Phase 3 CARDIO-TTRansform study</font> for
          transthyretin-mediated amyloid cardiomyopathy (ATTR-CM), a systemic, progressive and fatal condition that typically leads to progressive heart failure and often death within three-to-five years from disease onset. The CARDIO-TTRansform Phase 3
          study is fully enrolled with more than 1,400 patients &#8211; making it the largest study in this patient population to date.</div>
        <div><br>
        </div>
        <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">About WAINUA&#8482; (eplontersen)</div>
        <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">WAINUA&#8482; (eplontersen) is a ligand-conjugated antisense (LICA) medicine designed to inhibit the production of transthyretin, or TTR protein. WAINUA has been approved in
          the U.S. for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults (also referred to as ATTRv-PN). Please see full <font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal;">Prescribing

            Information</font></div>
        <div><br>
        </div>
        <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">
          <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">INDICATION for WAINUA<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">TM </sup>(eplontersen)</div>
          <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">WAINUA injection for subcutaneous use 45 mg is indicated for treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults.</div>
          <div style="font-size: 10pt;"><br>
          </div>
          <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">IMPORTANT SAFETY INFORMATION for WAINUA<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">TM </sup>(eplontersen)</div>
          <div style="font-size: 10pt;"><br>
          </div>
          <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">WARNINGS AND PRECAUTIONS</div>
          <div style="text-align: left; font-family: 'Times New Roman'; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Reduced Serum Vitamin A Levels and Recommended Supplementation </font><font style="font-size: 10pt;">WAINUA leads to a decrease in serum vitamin A levels. Supplement with recommended daily allowance of vitamin A. Refer patient to an ophthalmologist if ocular symptoms suggestive of vitamin A deficiency occur.</font></div>
          <div style="font-size: 10pt;"><br>
          </div>
          <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">ADVERSE REACTIONS</div>
          <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Most common adverse reactions (&#8805;9% in WAINUA-treated patients) were vitamin A decreased (15%) and vomiting (9%).</div>
          <div style="font-size: 10pt;"><br>
          </div>
          <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">Please see link to U.S. Full Prescribing Information for WAINUA.</div>
        </div>
        <div><br>
        </div>
        <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">About Hereditary Transthyretin-mediated Amyloid Polyneuropathy (ATTRv-PN)</div>
        <div><br>
        </div>
        <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">ATTRv-PN is caused by the accumulation of misfolded mutated TTR protein in the peripheral nerves. Patients with ATTRv-PN experience ongoing debilitating nerve damage
          throughout their body resulting in the progressive loss of motor functions, such as walking. These patients also accumulate TTR in other major organs, which progressively compromises their function. The damage from misfolded TTR protein
          accumulation leads to disability within five years of diagnosis and is generally fatal within a decade.</div>
        <div><br>
        </div>
        <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">About the NEURO-TTRansform Study</div>
        <div><br>
        </div>
        <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">NEURO-TTRansform is a global, open-label, randomized trial evaluating the efficacy and safety of eplontersen in patients with ATTRv-PN at week 35, week 66 and week 85.
          The final analysis comparing eplontersen to an external placebo group was completed at week 66. All patients were then followed on treatment until week 85 and evaluated four weeks after the last dose in an end-of-trial assessment. Following
          treatment and the end-of-trial assessments, patients were eligible to enter an open-label extension study to continue receiving eplontersen once every four weeks or enter a 20-week post-treatment evaluation period.</div>
        <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">&#160;</div>
        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
          <div style="page-break-after: always;" class="BRPFPageBreak">
            <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
        </div>
        <div><br>
        </div>
        <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">About Ionis Pharmaceuticals, Inc.</div>
        <div><br>
        </div>
        <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">For more than 30 years, Ionis has been a leader in RNA-targeted therapy, pioneering new markets and changing standards of care. Ionis currently has four marketed
          medicines and a promising late-stage pipeline highlighted by cardiovascular and neurological franchises. Our scientific innovation began and continues with the knowledge that sick people depend on us, which fuels our vision to become the leader
          in genetic medicine, utilizing a multi-platform approach to discover, develop and deliver life-transforming therapies.</div>
        <div><br>
        </div>
        <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">To learn more about Ionis visit <font style="font-size: 10pt; font-family: 'Times New Roman';">www.ionispharma.com</font> and follow us on Twitter @ionispharma.</div>
        <div><br>
        </div>
        <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Ionis&#8217; Forward-Looking Statements</div>
        <div><br>
        </div>
        <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">This press release includes forward-looking statements regarding Ionis' business and the therapeutic and commercial potential of WAINUA, Ionis' technologies and other
          products in development. Any statement describing Ionis' goals, expectations, financial or other projections, intentions or beliefs is a forward-looking statement and should be considered an at-risk statement. Such statements are subject to
          certain risks and uncertainties including those related to our commercial products and the medicines in our pipeline, and particularly those inherent in the process of discovering, developing and commercializing medicines that are safe and
          effective for use as human therapeutics, and in the endeavor of building a business around such medicines. Ionis' forward-looking statements also involve assumptions that, if they never materialize or prove correct, could cause its results to
          differ materially from those expressed or implied by such forward-looking statements. Although Ionis' forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently
          known by Ionis. As a result, you are cautioned not to rely on these forward-looking statements. These and other risks concerning Ionis' programs are described in additional detail in Ionis' annual report on Form 10-K for the year ended Dec. 31,
          2022, and the most recent Form 10-Q quarterly filing, which are on file with the Securities and Exchange Commission. Copies of these and other documents are available from the Company.</div>
        <div><br>
        </div>
        <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">In this press release, unless the context requires otherwise, "Ionis," "Company," "we," "our," and "us" all refer to Ionis Pharmaceuticals and its subsidiaries.</div>
        <div><br>
        </div>
        <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Ionis Pharmaceuticals<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup> is a registered trademark of Ionis Pharmaceuticals, Inc. WAINUA&#8482; is a trademark of AstraZeneca plc.</div>
        <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"> <br>
        </div>
        <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"> <br>
        </div>
        <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">
          <hr noshade="noshade" align="center" style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"> </div>
      </div>
    </div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>ions-20231221.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--Generated by Broadridge PROfile 23.12.1.5186 Broadridge-->
<xs:schema targetNamespace="http://ionispharma.com/20231221" elementFormDefault="qualified" xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:ions="http://ionispharma.com/20231221" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:us-types="http://fasb.org/us-types/2023" xmlns:srt-types="http://fasb.org/srt-types/2023">
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xlink:type="simple" xlink:href="ions-20231221_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="ions-20231221_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:roleType roleURI="http://ionispharma.com/role/DocumentAndEntityInformation" id="DocumentAndEntityInformation">
        <link:definition>000100 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:import namespace="http://fasb.org/us-gaap/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/dei/2023" schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/country/2023" schemaLocation="https://xbrl.sec.gov/country/2023/country-2023.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/currency/2023" schemaLocation="https://xbrl.sec.gov/currency/2023/currency-2023.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/exch/2023" schemaLocation="https://xbrl.sec.gov/exch/2023/exch-2023.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/naics/2023" schemaLocation="https://xbrl.sec.gov/naics/2023/naics-2023.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/sic/2023" schemaLocation="https://xbrl.sec.gov/sic/2023/sic-2023.xsd" />
  <xs:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <xs:import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/stpr/2023" schemaLocation="https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd" />
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xs:import namespace="http://www.xbrl.org/2004/ref" schemaLocation="http://www.xbrl.org/2004/ref-2004-08-10.xsd" />
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xs:import namespace="http://fasb.org/us-types/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd" />
  <xs:import namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" />
  <xs:import namespace="http://fasb.org/srt/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd" />
  <xs:import namespace="http://fasb.org/srt-types/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd" />
  <xs:import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd" />
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>ions-20231221_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--Generated by Broadridge PROfile 23.12.1.5186 Broadridge-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" />
  <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="CoverAbstract" xlink:title="CoverAbstract" />
    <link:label xlink:type="resource" xlink:label="dei_CoverAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_CoverAbstract_lbl" xml:lang="en-US" id="dei_CoverAbstract_lbl">Cover [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:title="label: CoverAbstract to dei_CoverAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="DocumentType" xlink:title="DocumentType" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentType_lbl" xml:lang="en-US" id="dei_DocumentType_lbl">Document Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentType" xlink:to="dei_DocumentType_lbl" xlink:title="label: DocumentType to dei_DocumentType_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="WrittenCommunications" xlink:title="WrittenCommunications" />
    <link:label xlink:type="resource" xlink:label="dei_WrittenCommunications_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_WrittenCommunications_lbl" xml:lang="en-US" id="dei_WrittenCommunications_lbl">Written Communications</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:title="label: WrittenCommunications to dei_WrittenCommunications_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="SolicitingMaterial" xlink:title="SolicitingMaterial" />
    <link:label xlink:type="resource" xlink:label="dei_SolicitingMaterial_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_SolicitingMaterial_lbl" xml:lang="en-US" id="dei_SolicitingMaterial_lbl">Soliciting Material</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:title="label: SolicitingMaterial to dei_SolicitingMaterial_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="PreCommencementTenderOffer" xlink:title="PreCommencementTenderOffer" />
    <link:label xlink:type="resource" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US" id="dei_PreCommencementTenderOffer_lbl">Pre-commencement Tender Offer</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:title="label: PreCommencementTenderOffer to dei_PreCommencementTenderOffer_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="PreCommencementIssuerTenderOffer" xlink:title="PreCommencementIssuerTenderOffer" />
    <link:label xlink:type="resource" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US" id="dei_PreCommencementIssuerTenderOffer_lbl">Pre-commencement Issuer Tender Offer</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:title="label: PreCommencementIssuerTenderOffer to dei_PreCommencementIssuerTenderOffer_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="AmendmentFlag" xlink:title="AmendmentFlag" />
    <link:label xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_AmendmentFlag_lbl" xml:lang="en-US" id="dei_AmendmentFlag_lbl">Amendment Flag</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:title="label: AmendmentFlag to dei_AmendmentFlag_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="DocumentFiscalYearFocus" xlink:title="DocumentFiscalYearFocus" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US" id="dei_DocumentFiscalYearFocus_lbl">Document Fiscal Year Focus</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:title="label: DocumentFiscalYearFocus to dei_DocumentFiscalYearFocus_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="DocumentFiscalPeriodFocus" xlink:title="DocumentFiscalPeriodFocus" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US" id="dei_DocumentFiscalPeriodFocus_lbl">Document Fiscal Period Focus</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:title="label: DocumentFiscalPeriodFocus to dei_DocumentFiscalPeriodFocus_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="DocumentPeriodEndDate" xlink:title="DocumentPeriodEndDate" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US" id="dei_DocumentPeriodEndDate_lbl">Document Period End Date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:title="label: DocumentPeriodEndDate to dei_DocumentPeriodEndDate_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="EntityRegistrantName" xlink:title="EntityRegistrantName" />
    <link:label xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityRegistrantName_lbl" xml:lang="en-US" id="dei_EntityRegistrantName_lbl">Entity Registrant Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:title="label: EntityRegistrantName to dei_EntityRegistrantName_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="EntityCentralIndexKey" xlink:title="EntityCentralIndexKey" />
    <link:label xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityCentralIndexKey_lbl" xml:lang="en-US" id="dei_EntityCentralIndexKey_lbl">Entity Central Index Key</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:title="label: EntityCentralIndexKey to dei_EntityCentralIndexKey_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="EntityFileNumber" xlink:title="EntityFileNumber" />
    <link:label xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityFileNumber_lbl" xml:lang="en-US" id="dei_EntityFileNumber_lbl">Entity File Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:title="label: EntityFileNumber to dei_EntityFileNumber_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="EntityTaxIdentificationNumber" xlink:title="EntityTaxIdentificationNumber" />
    <link:label xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US" id="dei_EntityTaxIdentificationNumber_lbl">Entity Tax Identification Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:title="label: EntityTaxIdentificationNumber to dei_EntityTaxIdentificationNumber_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="EntityIncorporationStateCountryCode" xlink:title="EntityIncorporationStateCountryCode" />
    <link:label xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US" id="dei_EntityIncorporationStateCountryCode_lbl">Entity Incorporation, State or Country Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:title="label: EntityIncorporationStateCountryCode to dei_EntityIncorporationStateCountryCode_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="EntityEmergingGrowthCompany" xlink:title="EntityEmergingGrowthCompany" />
    <link:label xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US" id="dei_EntityEmergingGrowthCompany_lbl">Entity Emerging Growth Company</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:title="label: EntityEmergingGrowthCompany to dei_EntityEmergingGrowthCompany_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="EntityAddressAddressLine1" xlink:title="EntityAddressAddressLine1" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US" id="dei_EntityAddressAddressLine1_lbl">Entity Address, Address Line One</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:title="label: EntityAddressAddressLine1 to dei_EntityAddressAddressLine1_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="EntityAddressAddressLine2" xlink:title="EntityAddressAddressLine2" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US" id="dei_EntityAddressAddressLine2_lbl">Entity Address, Address Line Two</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:title="label: EntityAddressAddressLine2 to dei_EntityAddressAddressLine2_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine3" xlink:label="EntityAddressAddressLine3" xlink:title="EntityAddressAddressLine3" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressAddressLine3_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US" id="dei_EntityAddressAddressLine3_lbl">Entity Address, Address Line Three</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:title="label: EntityAddressAddressLine3 to dei_EntityAddressAddressLine3_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="EntityAddressCityOrTown" xlink:title="EntityAddressCityOrTown" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US" id="dei_EntityAddressCityOrTown_lbl">Entity Address, City or Town</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:title="label: EntityAddressCityOrTown to dei_EntityAddressCityOrTown_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="EntityAddressStateOrProvince" xlink:title="EntityAddressStateOrProvince" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US" id="dei_EntityAddressStateOrProvince_lbl">Entity Address, State or Province</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:title="label: EntityAddressStateOrProvince to dei_EntityAddressStateOrProvince_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCountry" xlink:label="EntityAddressCountry" xlink:title="EntityAddressCountry" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressCountry_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressCountry_lbl" xml:lang="en-US" id="dei_EntityAddressCountry_lbl">Entity Address, Country</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:title="label: EntityAddressCountry to dei_EntityAddressCountry_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="EntityAddressPostalZipCode" xlink:title="EntityAddressPostalZipCode" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US" id="dei_EntityAddressPostalZipCode_lbl">Entity Address, Postal Zip Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:title="label: EntityAddressPostalZipCode to dei_EntityAddressPostalZipCode_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="CityAreaCode" xlink:title="CityAreaCode" />
    <link:label xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_CityAreaCode_lbl" xml:lang="en-US" id="dei_CityAreaCode_lbl">City Area Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:title="label: CityAreaCode to dei_CityAreaCode_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="LocalPhoneNumber" xlink:title="LocalPhoneNumber" />
    <link:label xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_LocalPhoneNumber_lbl" xml:lang="en-US" id="dei_LocalPhoneNumber_lbl">Local Phone Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:title="label: LocalPhoneNumber to dei_LocalPhoneNumber_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="Security12bTitle" xlink:title="Security12bTitle" />
    <link:label xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_Security12bTitle_lbl" xml:lang="en-US" id="dei_Security12bTitle_lbl">Title of 12(b) Security</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:title="label: Security12bTitle to dei_Security12bTitle_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_NoTradingSymbolFlag" xlink:label="NoTradingSymbolFlag" xlink:title="NoTradingSymbolFlag" />
    <link:label xlink:type="resource" xlink:label="dei_NoTradingSymbolFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US" id="dei_NoTradingSymbolFlag_lbl">No Trading Symbol Flag</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:title="label: NoTradingSymbolFlag to dei_NoTradingSymbolFlag_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="TradingSymbol" xlink:title="TradingSymbol" />
    <link:label xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_TradingSymbol_lbl" xml:lang="en-US" id="dei_TradingSymbol_lbl">Trading Symbol</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:title="label: TradingSymbol to dei_TradingSymbol_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="SecurityExchangeName" xlink:title="SecurityExchangeName" />
    <link:label xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_SecurityExchangeName_lbl" xml:lang="en-US" id="dei_SecurityExchangeName_lbl">Security Exchange Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:title="label: SecurityExchangeName to dei_SecurityExchangeName_lbl" />
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>ions-20231221_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--Generated by Broadridge PROfile 23.12.1.5186 Broadridge-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" />
  <link:roleRef roleURI="http://ionispharma.com/role/DocumentAndEntityInformation" xlink:type="simple" xlink:href="ions-20231221.xsd#DocumentAndEntityInformation" />
  <link:presentationLink xlink:type="extended" xlink:role="http://ionispharma.com/role/DocumentAndEntityInformation">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="CoverAbstract" xlink:title="CoverAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="DocumentType" xlink:title="DocumentType" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="DocumentType" xlink:title="presentation: CoverAbstract to DocumentType" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="AmendmentFlag" xlink:title="AmendmentFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="AmendmentFlag" xlink:title="presentation: CoverAbstract to AmendmentFlag" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="DocumentPeriodEndDate" xlink:title="DocumentPeriodEndDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="DocumentPeriodEndDate" xlink:title="presentation: CoverAbstract to DocumentPeriodEndDate" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="DocumentFiscalYearFocus" xlink:title="DocumentFiscalYearFocus" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="DocumentFiscalYearFocus" xlink:title="presentation: CoverAbstract to DocumentFiscalYearFocus" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="DocumentFiscalPeriodFocus" xlink:title="DocumentFiscalPeriodFocus" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="DocumentFiscalPeriodFocus" xlink:title="presentation: CoverAbstract to DocumentFiscalPeriodFocus" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="EntityFileNumber" xlink:title="EntityFileNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityFileNumber" xlink:title="presentation: CoverAbstract to EntityFileNumber" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="EntityRegistrantName" xlink:title="EntityRegistrantName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityRegistrantName" xlink:title="presentation: CoverAbstract to EntityRegistrantName" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="EntityCentralIndexKey" xlink:title="EntityCentralIndexKey" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityCentralIndexKey" xlink:title="presentation: CoverAbstract to EntityCentralIndexKey" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="EntityIncorporationStateCountryCode" xlink:title="EntityIncorporationStateCountryCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityIncorporationStateCountryCode" xlink:title="presentation: CoverAbstract to EntityIncorporationStateCountryCode" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="EntityTaxIdentificationNumber" xlink:title="EntityTaxIdentificationNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityTaxIdentificationNumber" xlink:title="presentation: CoverAbstract to EntityTaxIdentificationNumber" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="EntityAddressAddressLine1" xlink:title="EntityAddressAddressLine1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressAddressLine1" xlink:title="presentation: CoverAbstract to EntityAddressAddressLine1" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="EntityAddressAddressLine2" xlink:title="EntityAddressAddressLine2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressAddressLine2" xlink:title="presentation: CoverAbstract to EntityAddressAddressLine2" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine3" xlink:label="EntityAddressAddressLine3" xlink:title="EntityAddressAddressLine3" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressAddressLine3" xlink:title="presentation: CoverAbstract to EntityAddressAddressLine3" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="EntityAddressCityOrTown" xlink:title="EntityAddressCityOrTown" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressCityOrTown" xlink:title="presentation: CoverAbstract to EntityAddressCityOrTown" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="EntityAddressStateOrProvince" xlink:title="EntityAddressStateOrProvince" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressStateOrProvince" xlink:title="presentation: CoverAbstract to EntityAddressStateOrProvince" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCountry" xlink:label="EntityAddressCountry" xlink:title="EntityAddressCountry" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressCountry" xlink:title="presentation: CoverAbstract to EntityAddressCountry" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="EntityAddressPostalZipCode" xlink:title="EntityAddressPostalZipCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressPostalZipCode" xlink:title="presentation: CoverAbstract to EntityAddressPostalZipCode" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="CityAreaCode" xlink:title="CityAreaCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="CityAreaCode" xlink:title="presentation: CoverAbstract to CityAreaCode" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="LocalPhoneNumber" xlink:title="LocalPhoneNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="LocalPhoneNumber" xlink:title="presentation: CoverAbstract to LocalPhoneNumber" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="Security12bTitle" xlink:title="Security12bTitle" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="Security12bTitle" xlink:title="presentation: CoverAbstract to Security12bTitle" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="TradingSymbol" xlink:title="TradingSymbol" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="TradingSymbol" xlink:title="presentation: CoverAbstract to TradingSymbol" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_NoTradingSymbolFlag" xlink:label="NoTradingSymbolFlag" xlink:title="NoTradingSymbolFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="NoTradingSymbolFlag" xlink:title="presentation: CoverAbstract to NoTradingSymbolFlag" order="21.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="SecurityExchangeName" xlink:title="SecurityExchangeName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="SecurityExchangeName" xlink:title="presentation: CoverAbstract to SecurityExchangeName" order="22.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="EntityEmergingGrowthCompany" xlink:title="EntityEmergingGrowthCompany" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityEmergingGrowthCompany" xlink:title="presentation: CoverAbstract to EntityEmergingGrowthCompany" order="23.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="WrittenCommunications" xlink:title="WrittenCommunications" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="WrittenCommunications" xlink:title="presentation: CoverAbstract to WrittenCommunications" order="24.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="SolicitingMaterial" xlink:title="SolicitingMaterial" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="SolicitingMaterial" xlink:title="presentation: CoverAbstract to SolicitingMaterial" order="25.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="PreCommencementTenderOffer" xlink:title="PreCommencementTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="PreCommencementTenderOffer" xlink:title="presentation: CoverAbstract to PreCommencementTenderOffer" order="26.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="PreCommencementIssuerTenderOffer" xlink:title="PreCommencementIssuerTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="PreCommencementIssuerTenderOffer" xlink:title="presentation: CoverAbstract to PreCommencementIssuerTenderOffer" order="27.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>logo1.jpg
<TEXT>
begin 644 logo1.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  (! 0(! 0(" @(" @(" P4# P,#
M P8$! ,%!P8'!P<&!P<("0L)" @*" <'"@T*"@L,# P,!PD.#PT,#@L,# S_
MVP!# 0(" @,# P8# P8," <(# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# S_P  1"  W )@# 2(  A$! Q$!_\0
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MPE_V(-G_ .G'4J];_P"#7#_7?%S_ '=/_G-7W%?_ )$:]%^:/ZCS/_DUT?\
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M>..*<OR^O#.,M6L6E./O4U?3WU>6G75J[T:/=M-^%^EV'BE-<=#/K&P"2Y8
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M_L 6_P#Z4"O5SAPEEU24-FD_Q1^@>(M2A5X/Q5;#-.$XQDFMG><7?Y[G=?\
M!TW_ ,@?X)_]=M:_E85X9_P;7_\ )^&J_P#8KW7_ *-AKW/_ (.F_P#D#_!/
M_KMK7\K"O#/^#:__ )/PU7_L5[K_ -&PUYF'_P"1&_27_I3/B<E_Y-;/_!5_
M].2/VQ^.MQX+M?A%K[_$0Z&O@H6C#5SK&S[%Y)P#YF_Y<9(QWSC'.*_/?XZ_
M\&XOPI^,UN?$'PJ\97OA:WU-/M-K#N75=+=6Y4Q/N#[/3YW^M>5?\'(GQ/\
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>ZG?F?%V=9C3]CC<5.<.SD[?-;/YGK-%%%<9\X?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>7
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm139739629759456">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Dec. 21, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 21,  2023<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">000-19125<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">IONIS PHARMACEUTICALS, INC.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000874015<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">33-0336973<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">2855 Gazelle Court<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Carlsbad<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">92010<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">760<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">931-9200<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $.001 Par Value<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">IONS<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>ef20017247_form8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="ions-20231221.xsd" xlink:type="simple"/>
    <context id="c20231221to20231221">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
        </entity>
        <period>
            <startDate>2023-12-21</startDate>
            <endDate>2023-12-21</endDate>
        </period>
    </context>
    <dei:AmendmentFlag
      contextRef="c20231221to20231221"
      id="Fact_08f36272673a41639eb79c935ec285bd">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="c20231221to20231221"
      id="Fact_1ca1adae07104a16ab67f2e2f244dc4d">0000874015</dei:EntityCentralIndexKey>
    <dei:EntityAddressStateOrProvince
      contextRef="c20231221to20231221"
      id="Fact_0ffbb164a53e46cd96f7d165925db3ab">CA</dei:EntityAddressStateOrProvince>
    <dei:DocumentType
      contextRef="c20231221to20231221"
      id="Fact_89b20f448000484a99378cc870c89f20">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="c20231221to20231221"
      id="Fact_95f843f3b2e044e5829f63a6fee94472">2023-12-21</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName
      contextRef="c20231221to20231221"
      id="Fact_f0eac010c4ef4cc79b535e678e24bdb6">IONIS PHARMACEUTICALS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="c20231221to20231221"
      id="Fact_a946e6491aa24db190b18e8d84b2e900">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="c20231221to20231221"
      id="Fact_94cfa8cd7b324aaebeb3c76e92900d06">000-19125</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber
      contextRef="c20231221to20231221"
      id="Fact_dd23466dc8e9489f826cad885ea0271a">33-0336973</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="c20231221to20231221"
      id="Fact_e9ac437091c44ab58b8a5dbe2685e435">2855 Gazelle Court</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="c20231221to20231221"
      id="Fact_8192bcc8d18441358b3171e8d46de8e4">Carlsbad</dei:EntityAddressCityOrTown>
    <dei:EntityAddressPostalZipCode
      contextRef="c20231221to20231221"
      id="Fact_33aa7c5ae18b44ecb7a801eb3ce20cb4">92010</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="c20231221to20231221"
      id="Fact_93d2a473fc3643edbef4cb32ddff945c">760</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="c20231221to20231221"
      id="Fact_aa9b67e90712488a884e99d54f2e0c6e">931-9200</dei:LocalPhoneNumber>
    <dei:WrittenCommunications
      contextRef="c20231221to20231221"
      id="Fact_45bcea51a37d4c56ab869e6f16ac6ca2">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="c20231221to20231221"
      id="Fact_2cf270e88d4b4a4cac0b2556b9da4630">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="c20231221to20231221"
      id="Fact_b7cc4a902dde4bb7823889967a191323">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="c20231221to20231221"
      id="Fact_3d11b2f6aa8848ea864d70236c9ea162">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle
      contextRef="c20231221to20231221"
      id="Fact_98579f8db1df496c9332dd09158e555d">Common Stock, $.001 Par Value</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="c20231221to20231221"
      id="Fact_d3aaf440913c4fb19c44fe6b95d3296d">IONS</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="c20231221to20231221"
      id="Fact_8b6374e783fb4760bf287cd657c8e896">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany
      contextRef="c20231221to20231221"
      id="Fact_050419c23fbe4f628d24e8e02c9547b8">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>9
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5
MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$%     @
M::.55R 5S]=3!   D1   !@   !X;"]W;W)K<VAE971S+W-H965T,2YX;6R=
MF&UOHT80Q[_*BE95*SF!Q<^I;<DAR9UU>7"#[TYJU1=K6-NK ,LM2YSTTW<6
MV^#>X<'JFY@%YL^/V>$_NQEMI7K)-IQK\A9'23:V-EJG5[:=!1L>L^Q2ICR!
M*RNI8J9AJ-9VEBK.PB(HCFS7<7IVS$1B34;%N;F:C&2N(Y'PN2)9'L=,O5_S
M2&['%K4.)Y[%>J/-"7LR2MF:^UQ_3N<*1G:I$HJ8)YF0"5%\-;:F].K:[9B
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MIR1-\SR. !9GD*88 J<11S &P %#TG1X#SY['R73>RHY_U=3_ 102P,$%
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M>FR-9V87YTC'?8Q']>5=2(6NF9MYEJ6R!F_236P@R*2*Y U+2X<L-03&IAJ
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M4')O<',O8V]R92YX;6Q02P$"% ,4    " !IHY57F5R<(Q &  "<)P  $P
M            @ '+ 0  >&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0    (
M &FCE5<@%<_74P0  )$0   8              " @0P(  !X;"]W;W)K<VAE
M971S+W-H965T,2YX;6Q02P$"% ,4    " !IHY57GZ ;\+$"  #B#   #0
M            @ &5#   >&PO<W1Y;&5S+GAM;%!+ 0(4 Q0    ( &FCE5>7
MBKL<P    !,"   +              "  7$/  !?<F5L<R\N<F5L<U!+ 0(4
M Q0    ( &FCE5<<.&7J/P$  #P"   /              "  5H0  !X;"]W
M;W)K8F]O:RYX;6Q02P$"% ,4    " !IHY57)!Z;HJT   #X 0  &@
M        @ '&$0  >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4
M    " !IHY5799!YDAD!  #/ P  $P              @ &K$@  6T-O;G1E
C;G1?5'EP97-=+GAM;%!+!08     "0 ) #X"  #U$P     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.23.4</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>22</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="ef20017247_form8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>000100 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ionispharma.com/role/DocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" isUsgaap="true" original="ef20017247_form8k.htm">ef20017247_form8k.htm</File>
    <File>ions-20231221.xsd</File>
    <File>ions-20231221_lab.xml</File>
    <File>ions-20231221_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="22">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>15
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "ef20017247_form8k.htm": {
   "nsprefix": "ions",
   "nsuri": "http://ionispharma.com/20231221",
   "dts": {
    "inline": {
     "local": [
      "ef20017247_form8k.htm"
     ]
    },
    "schema": {
     "local": [
      "ions-20231221.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2004/ref-2004-08-10.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd",
      "https://xbrl.sec.gov/country/2023/country-2023.xsd",
      "https://xbrl.sec.gov/currency/2023/currency-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd",
      "https://xbrl.sec.gov/exch/2023/exch-2023.xsd",
      "https://xbrl.sec.gov/naics/2023/naics-2023.xsd",
      "https://xbrl.sec.gov/sic/2023/sic-2023.xsd",
      "https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "ions-20231221_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "ions-20231221_pre.xml"
     ]
    }
   },
   "keyStandard": 22,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 3,
    "http://xbrl.sec.gov/dei/2023": 3
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 29,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2023": 22
   },
   "report": {
    "R1": {
     "role": "http://ionispharma.com/role/DocumentAndEntityInformation",
     "longName": "000100 - Document - Document and Entity Information",
     "shortName": "Document and Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c20231221to20231221",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20017247_form8k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c20231221to20231221",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20017247_form8k.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://ionispharma.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "TradingSymbol",
     "presentation": [
      "http://ionispharma.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://ionispharma.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://ionispharma.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://ionispharma.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://ionispharma.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://ionispharma.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://ionispharma.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://ionispharma.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://ionispharma.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://ionispharma.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://ionispharma.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://ionispharma.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://ionispharma.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://ionispharma.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://ionispharma.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://ionispharma.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12bTitle",
     "presentation": [
      "http://ionispharma.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://ionispharma.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://ionispharma.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "dei_EntityAddressAddressLine3": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine3",
     "presentation": [
      "http://ionispharma.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Three",
        "documentation": "Address Line 3 such as an Office Park"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://ionispharma.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://ionispharma.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_NoTradingSymbolFlag": {
     "xbrltype": "trueItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "NoTradingSymbolFlag",
     "presentation": [
      "http://ionispharma.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Trading Symbol Flag",
        "documentation": "Boolean flag that is true only for a security having no trading symbol."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://ionispharma.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://ionispharma.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://ionispharma.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://ionispharma.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Section": "14a",
   "Number": "240",
   "Subsection": "12"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>16
<FILENAME>0001140361-23-058974-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001140361-23-058974-xbrl.zip
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MPG6]6=D43;X"M"ZIW^M.VG-TJ(DVI5*[(99MD&FM6D _E8]:5?6S6J;#- /
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MD@GJ0N0'G>R\ MEZS/R>)"S-0-)T<D.[V]TRM]!->7.Z:4!<X9( 4VH1'N+
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M4)*+5\$)3\YJKP/2B )?\]T9<]=F3Y_WV^IZ_@-]8W\QB.'A_P%02P,$%
M  @ ::.55\0@K(%$ P  0P\  !$   !I;VYS+3(P,C,Q,C(Q+GAS9+576V_;
M(!1^G[3_P/R.KVW51$VK36VG2MTZ=9NTMXE@G*!A[ %NDW\_P,9QKHOC[0W#
M^2X<SB'DZF:1,_!"A*0%GWB1'WJ <%RDE,\F7B4ADIA2[^;Z[9NK=Q!^))P(
MI$@*IDOP010H%32=$?#E^2FCC( X\:/8C_SSZ/*BLPZAP2_D6.(YR1%02,R(
M^HQR(DN$R<2;*U6.@T![H+*<(Y$C'Q=Y$(=Q$L5QI#TQDA.N[@N1WY(,54Q-
MO-\58C2C)/6 W@27XX5LF5Y?7_W7Q"_$3).$4?#CT^-7J^UBM90\0K<.9I3_
M6J->3 5SY$E@EJ=(DM;'5GQC)1J-1H%=;4,U$3U 3;E4B&/2C4]5"^@&GP?U
MH@M-"5V/DP3[L^(ET MVAVV@$E M2R)W^]#+@5DVF!B&"4S:O.CZ6 =F2$XM
MR*VL"4FA]L6W2S5 EPL IF 0YX5"2A^0G6HFRY+RK&AF])S)Z-B=PC/)@,WQ
MV!!./$GSDID$VKFY(-G$,Z</W2G_+ 7QM4,7(@I&#AR)60XT1.IZM,X>5\*.
M @F\Q;)5 YJD*(E05.]Z54+!/]L60].^V](0PO[O?@S/-[T#8 ;?GQ_V-J$U
M=%O@RC3^>Y[><475\D$?O(XP>?< 32?>P8A6VZFG)*.<VGH*];T0A@ "Q] =
M(IZ"F@YT^*Z"39)-_DJ2](E?V_%FC33H)N00$B.&*W8"<.5L/ZZ9=>?@^BK8
M:*QZ8KW]3//ILBN$ GSK\N[V_@RALFG]^LI_++"EJ:.ENY)V8@+"E'0SMIS]
MA4Q=)1WTL.>>.^AA,]P,!JCBHN)*+/LH=R'N8XB#2@C]&][/0A?3?@TP019X
MWL= &V]' X0YHECV45X!ZN$ ;4EQ'V47;@;]5#>O[U%]6W(R,X^SW?*;,";$
M&@H:'AC%,+H8[D/U]J!.T5]/IRI%K_2[>#L:=@#=E]HQ&[<0\P4=SFP_,=M/
MHI-=G 7"_&8?:<!&&]DS&%["*.R7]:U7YY&J#F"$SX^6W/>P'/#K8FF&MEWS
M,-+^L()D43+$D2K$\EY_']\"79:[%<DI'=%]4??*D8NO\V/>X[U2L^\E?[+Z
MT./9^;=EGYF_(>VW7!FQCZ.:[/H/4$L#!!0    ( &FCE5>-!,],@ @  '58
M   5    :6]N<RTR,#(S,3(R,5]L86(N>&ULS9Q=;]LV%(;O!^P_<-[-!M1V
M+6/%$C0NLC0M@J5)D*38%X9"EFE'F"P&E-PX_WZD)-HB>4@I%27KIG5XWO/R
MZSF2K$1Z^VZ[CM!73).0Q">#R>CU .$X((LP7IT,-LG03X(P'+R;??_=VQ^&
MPX\XQM1/\0+-G]%OE/@+&BY6&-W<7B_#""-O.IIXH\GHE\FO;TKQX9#G1V'\
MWS'_9^XG&+%^X^1XFX0G@X<T?3P>CY^>GD9/TQ&AJ['W^O5D_.>GR[O@ :_]
M81@GJ1\'>("8_CC)&B])X*?9H$OIVSF-A,%TO.O+J. _#85LR)N&$V\XG8RV
MR6)0#)&':W0BY%M-7\QI<G1T-,ZB.RDS"BW6NVFSU4,H7S]*(GR+EXC___GV
MPIA]-.:*<8S32W^.(]9EEIX^/^*301*N'R,LVAXH7L(^$:4[&[XZ1WQU)F_X
MZORX=QXW&=Z*TW1/4C]R,\[,3Q^KUDWS05^Y6EK;D*]<KC*K<MS!*I>Z:3[H
M&TQ#LCB/%^T/7.W*U>#O4I]V@(K>6?,)M#]J8*@1;[IDGZ1^\3;%\0(O1,_<
MVW+LS+K.#K:9\\Z;!))KQ,\BA.K329AKYIC@8+0B7\<+'#)G;\H_#/F';!;L
MAR]GA)T_3^=)2OT@%4[9)$X&8"P-4SYV)3:6!\KSI:%2G) -#;#2@S:"+]$\
M>M$B27N<#\UDNHY8M_S* ,?#SW<#%"Y,VEG6A/X1C?^^'>]'K<_TE,K[XM-
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MMY=V'#:6<,P/B!^?;R/BC_BQ]L?_ 5!+ 0(4 Q0    ( &FCE5>PBGNO=!4
M "]4   5              "  0    !E9C(P,#$W,C0W7V5X.3DM,2YH=&U0
M2P$"% ,4    " !IHY57LON^=%(1  #Q9   %0              @ &G%0
M968R,# Q-S(T-U]F;W)M.&LN:'1M4$L! A0#%     @ ::.55\0@K(%$ P
M0P\  !$              ( !+"<  &EO;G,M,C R,S$R,C$N>'-D4$L! A0#
M%     @ ::.55XT$STR "   =5@  !4              ( !GRH  &EO;G,M
M,C R,S$R,C%?;&%B+GAM;%!+ 0(4 Q0    ( &FCE5>IIW&<WP4  /@^   5
M              "  5(S  !I;VYS+3(P,C,Q,C(Q7W!R92YX;6Q02P4&
/  4 !0!+ 0  9#D

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
